Cantor Fitzgerald analyst Brandon Folkes believes the announcement that Alkermes (ALKS) and Amneal Pharmaceuticals (AMRX) have settled their IPR challenge over Vivitrol removes one of the overhangs on Alkermes stock. The analyst views the settlement, allowing Amneal entry in 2028, as a positive for Alkermes given the fact that about 64% of instituted IPR challenges find that all claims are unpatentable. That said, he believes that consensus estimates for Vivitrol had assumed an Alkermes win in the IPR challenge given the strong growth in consensus Vivitrol sales through 2024, and believes estimates leave little room for upward earnings revisions. Folkes reiterates a Neutral rating and $26 price target on Alkermes' shares.

Amneal Pharmaceuticals announced the availability of Over the Counter, or OTC, Naloxone Hydrochloride, or Naloxone HCI, Nasal Spray, USP, 4mg, following Abbreviated New Drug Application, or ANDA, approval from the FDA. Amneal's Naloxone HCI Nasal Spray, manufactured in the U.S., is a generic equivalent to OTC Narcan HCI Nasal Spray, a medication that is widely used to help treat drug overdose from opioids, including heroin, fentanyl and prescription opioid medications.